Project/Area Number |
25461680
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | Kurume University |
Principal Investigator |
ISHII Norito 久留米大学, 医学部, 准教授 (80330827)
|
Co-Investigator(Kenkyū-buntansha) |
HASHIMOTO Takashi 久留米大学, 皮膚細胞生物学研究所, 教授 (20129597)
HAMADA Takahiro 久留米大学, 医学部皮膚科, 講師 (40320204)
OHYAMA Bungo 久留米大学, 医学部皮膚科, 講師 (90461441)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 皮膚診断学 / 自己免疫性水疱症 / 水疱性類天疱瘡 / 皮膚免疫学 |
Outline of Final Research Achievements |
Autoantibodies to BP180, but not BP230, are considered to be pathogenic in bullous pemphigoid (BP). To confirm the presence of BP patients reactive exclusively with BP230 and to study clinical and immunological characteristics in this condition, BP patients were divided into three groups; i.e., BP reactive only with BP230 (BP230-BP), BP reactive with both BP180 and BP230 (BP180-BP230-BP) and BP reactive only with BP180 (BP180-BP), by the results of standard ELISAs of BP180 and BP230. We propose a new disease entity, named anti-BP230-type BP, in which anti-BP230 antibodies might be pathogenic and react specifically with the BP230 C-terminal domain. While anti-BP230 antibodies in BP180-BP230-BP seem to be produced via intermolecular epitope spreading, anti-BP230 antibodies in BP230-BP are considered to be produced by different mechanisms.
|